• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconDrugs

Drugs

Page 30 of 32
Inside of a Gilead Sciences Lab
Tech
Drugmaker Alexion boosts its rare drug pipeline with $8.4 billion deal
By ReutersMay 6, 2015
PA: Mylan Headquarters
Finance
Mylan goes big with $29 billion offer to buy Perrigo
By Laura LorenzettiApril 8, 2015
States ask U.S. Congress to launch inquiry of herbal supplements
Retail
States ask U.S. Congress to launch inquiry of herbal supplements
By ReutersApril 2, 2015
IL: Corporations In Illinois
Features
Takeda’s ready to shell out $2.2 billion to settle Actos drug cases
By Laura LorenzettiApril 1, 2015
Where do CEOs with addictions go when they hit bottom?
Leadership
Where do CEOs with addictions go when they hit bottom?
By Daniel BukszpanMarch 25, 2015
Merck
Features
Merck halts study in light of melanoma drug’s success
By Laura LorenzettiMarch 24, 2015
George Scangos, CEO of Biogen Inc. speaks during Reuters Health Summit in New York
Features
How Biogen scored the most successful Alzheimer’s drug so far
By Jen WiecznerMarch 20, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Finance
Valeant comes out a winner after upping its Salix bid to $11.1 billion
By Laura LorenzettiMarch 16, 2015
Logo of Swiss drugmaker Novartis is seen at its headquarters in Basel
Features
FDA approves the first biosimilar for the U.S. market
By Laura LorenzettiMarch 6, 2015
IL: Corporations In Illinois
Finance
AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal
By ReutersMarch 4, 2015
Inside Rite Aid Ahead of Earnings Reports
Retail
Rite Aid takes aim at CVS with a $2 billion purchase
By Laura LorenzettiFebruary 11, 2015
161135392
Features
Biosimilars may one day save your life. But what are they?
By Laura LorenzettiFebruary 6, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Finance
After Allergan loss, is Valeant dumpster diving?
By Jen WiecznerJanuary 31, 2015
Picture taken on January 15, 2012 in Lil
Commentary
How to stop generic drug shortages: end hospital group purchasing kickbacks 
By Phillip L. Zweig and Robert A. CampbellJanuary 30, 2015
Los Angeles City Council Votes To Ban Medical Marijuana Dispensaries
Retail
Report predicts 18 states will legalize pot by 2020
By TIMEJanuary 26, 2015
1...
  • 28
  • 29
  • 30
  • 31
  • 32
32
Most Popular
Arts & Entertainment
Ed Sheeran asked Patriots owner Robert Kraft for $2 million aid donation after Macklemore was dropped from his tour for pro-Palestine commentsplaceholder alt text
By Marco Quiroz-GutierrezSeptember 18, 2026
C-Suite
Meet Warren Buffett's son Howard, a former sheriff, war photographer, and now, Berkshire's new chairmanplaceholder alt text
By Catherina GioinoSeptember 18, 2026
Success
Billionaire TikTok founder is now the richest person in all of Asia, with a $105 billion net worth—he's gained $92 billion since 2019 thanks to AIplaceholder alt text
By Emma BurleighSeptember 17, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.